ghk-cu peptide cons The Effect of the Human GHK on Gene Expression Relevant to Nervous System Function and Cognitive Decline GHK-Cu & Appetite — misunderstood
Description
Most common adverse events at all doses: Nausea (3355%, dose-related) Vomiting (1335%) Decreased appetite (1528%) Constipation or diarrhea (1020%) Injection-site reaction (510%) Dose-related dysesthesia signal: The TRIUMPH-4 trial identified a dose-related dysesthesia (nerve-tingling, paresthesia) signal: This is the most-flagged trial-level safety signal for retatrutide and the reason community doses cluster at 2-4 mg/week well below where the dysesthesia signal becomes prominent
As we age, NAD+ levels decline, leading to decreased energy and cognitive function

A 52-year-old marathon runner once brought me B12 of 1280 pg/mL and AST 89 IU/L

Why Are Injections Recommended for Pain Management

Table 3 summarizes RCTs of the dual and triple GLP1-RA use in obesity
